Get Live Data

Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE
Andrada Mining acquisition elevates the miner to emerging mid-tier status
Andrada Mining acquisition elevates the miner to emerging mid-tier statusView Video

Latest Share Chat

  2. Share Prices
  3. Reneuron Share Price
  4. Reneuron Share News
  5. UK DIRECTOR DEALINGS SUMMARY: ASOS CEO Sells GBP20 Million In Shares

Pin to quick picksReneuron Share News (RENE)

Reneuron Information
  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK DIRECTOR DEALINGS SUMMARY: ASOS CEO Sells GBP20 Million In Shares

Fri, 30th Jan 2015 12:45

Director Dealings Summary - Week Ended January 30        
Company Name Position Buy or Sell Number of Shares Resulting Holding *Note
3i Group Caroline Banszky Non-Executive Director Buy 6,000 undisclosed Same day as dilluted net aset value increased 5%
ASOS Nick Robertson CEO Sold 744,600 7 million Deal worth GBP20 million
Braemar Shipping Jürgen Breuer Non-Executive Director Buy 6,000 6,000 First purchase
Brewin Dolphin Paul Wilson Director Buy 8,596 8,596  
Burberry Carolyn McCall Non-Executive Director Buy 1,117 undisclosed McCall also is CEO of easyJet
Bushveld Minerals Ian Watson Chairman Buy 540,000 undisclosed  
Crest Nicholson Steve Evans Production Director Sold 350,000 307,765 Same day as company reported profit increase
Daily Internet Michael Edelson Chairman Buy 6.3 million 27.6 million  
Daily Internet Christopher Evans CEO Buy 369,485 19.6 million  
Flybe Simon Laffin Chairman Buy 6,728 288,000 Same day as shares hit 14-month low
Foreign & Colonial Investment Trust  Christopher Keljik  Non-Executive Director Buy 9,000 72,001  
IG Group Stephen Hill Non-Executive Director Sold 42,000 79,324 Same day as Ex-dividend date
JPMorgan Smaller Cos Michael Quicke Chairman Buy 4.879 9,212  
JPMorgan Smaller Cos Andrew Robson Non-Executive Director Buy 1,000 2,163  
Learning Technologies Jonathan Satchell CEO Sold 3 million 110.2 million 11 days after saying  FY results to be ahead of expectations
Learning Technologies Leslie-Ann Reed Non-Executive Director Buy 750,000 750,000  
Learning Technologies Neil Elton Non-Executive Director Buy 160,000 160,000  
Kingfisher Ian Cheshire Director Sold 16,000 undisclosed Stood down as CEO on December, 8 2014
Kingfisher Kate Cheshire Spouse Sold 15,000 undisclosed  
Miton Group Gervais Williams MD Buy 295,000 9.1 million  
Porvair Raj Rajagopal Non-Executive Director Buy 15,000 15,000  
Proactis Sean McDonough COO Sold 100,000 121,666 Sold to other directors
Proactis Alan Aubrey Chairman Buy 25,000 1.1 million  
Proactis Rod Jones CEO Buy 25,000 1.9 million  
Proactis Tim Sykes CFO Buy 25,000 148,001  
Proactis Rodney Potts Non-Executive Director Buy 25,000 8.9 million  
ReNeuron Olav Hellebø CEO Buy 322,778 322,778  
ReNeuron Michael Hunt CFO Buy 161,556 1.5 million  
Telecom Plus Charles Wigoder Chairman Buy 25,000 16 million  
Telecom Plus Julian Schild Non-Executive Director Buy 25,000 158,682  
Telecom Plus Melvin Lawson Non-Executive Director Buy 25,000 2.1 million  
WYG Graham Olver COO Sold 23,404 1.9 million share options 2 days after WYG launched review into selling the company
WYG Louise Olver Spouse Sold 64,322 Nil  
             
*Note: A recent company event around the time of the dealing does not suggest the dealing took place because of that event.
When a spouse or related party to a director buys shares, the resulting holding is the beneficial holding of the director
             
Contact: +44 207 199 0340; newsroom@alliancenews.com; @AllNewsTeam    
             
Copyright 2015 Alliance News Limited. All Rights Reserved.        

More News
12 Jul 2010 07:27

ReNeuron Group To Present New Data Of Lead CTX Stem Cell Line

LONDON (Dow Jones)--ReNeuron Group PLC (RENE.LN), a clinical-stage stem cell business, said Monday it will present important new data regarding the mechanisms of action of its lead CTX stem cell line in pre-clinical models of brain damage. MAIN FACTS: -The results of these studies will be pr

Read more
29 Jun 2010 07:51

ReNeuron Group FY Pretax Loss GBP6.2M On Revenue GBP31,000

LONDON (Dow Jones)--ReNeuron Group PLC (RENE.LN) said Tuesday that for the year ended March 31, it made a pretax loss of GBP6.2 million on revenue of GBP31,000. MAIN FACTS: -Revenue GBP31,000 (2009: GBP93,000) -Operating loss GBP6.2 million (2009: loss GBP4.7 million) -Pretax loss GB

Read more
28 Jan 2010 13:48

Sector movers: Drug sector off colour

The pharmaceuticals sector fell back after AstraZeneca posted a 10% rise in fourth quarter earnings, but predicted 2010 revenues would be hit by the loss of exclusive rights to sell certain drugs. The company is also planning to cut 8,000 jobs from its global workforce of 63,000. While Astra falls

Read more
28 Jan 2010 11:25

Small caps round-up: Xcite, ReNeuron, CPL Resources

Shares in Xcite Energy jumped after the oil group said its subsidiary Xcite Energy Resources has concluded an agreement with BP subsidiary BP Oil International to market and sell Xcite's crude oil from the Bentley field in the North Sea. ReNeuron group climbed after the stem cell developer said Pha

Read more
11 Jan 2010 16:41

London close: Footsie gives up gains

The leading share index gave up early gains to finish only slightly higher as euphoria over strong trade figures from China in December gave way to renewed fears over recovery prospects. China's December imports jumped by 55.9% from the same month the previous year, while exports were 17.7% higher

Read more
11 Jan 2010 14:16

London afternoon: Stocks back on the climb

Leading shares, which had been surrendering early gains at the end of the morning, picked up again over the lunch time session, helped by expectations of a firm start by Wall Street. In the absence of much in the way of corporate events to attract attention, traders have been focused on broker note

Read more
11 Jan 2010 08:44

ReNeuron poised for stroke treatment trials

Stem cell therapy group ReNeuron said it is on track to start human trials of its flagship treatment ReN001 for disabled stroke patients in the first quarter of this year. ReNeuron said it has submitted extra data for the UK's Gene Therapy Advisory Committee. If a successful review of the data is r

Read more
26 Nov 2009 14:45

Small caps round-up: Hampson Industries, Bezant, Tangent Comms...

Aerospace and engineering group Hampson Industries reported a 32% slump in first half profit before tax to £11m on revenue down 12% to £97m. "Although the immediate outlook for our core markets remains uncertain, present customer indications and the scale of new work in the pipeline all point to a

Read more
16 Nov 2009 11:54

Small caps round-up: Ocean Wilsons, Fortune Oil, Freshwater...

PR and marketing group Freshwater's profits fell sharply last year, but the fourth quarter saw an improvement that has continued into the current year. Pre-tax profit fell to £0.24m from £1.17m, on sales of £9.1m down from £9.5m. "Profitability improved in the second half, and we have gone into th

Read more
2 Oct 2009 15:33

ReNeuron boosted by study findings

Shares in stem cell developer ReNeuron were wanted after the company drew attention to the publication of new research using the company's ReNcell neural stem cell products. Researchers based in California have developed a safe strategy for reprogramming cells to a pluripotent (capable of affecting

Read more
17 Sep 2009 08:39

Small caps round-up: Byotrol, ReNeuron, Accuma...

Germ-killing product supplier Byotrol said it has seen a significant increase in orders and now expects results for the financial year to September 30 to be ahead of expectations. Shares in Meridian Petroleum gushed higher after the oil and gas firm announced an increase in prospective resources in

Read more
8 Jul 2009 13:44

Sector movers: Astra lifts drug stocks after broker boost

Pharmaceutical stocks are higher after the broker Panmure Gordon said AstraZeneca was set to benefit from US rivals that produce generic alternatives to its cancer drug Casodex being too slow off the mark. AstraZeneca's slight rise is not as impressive as that of stem cell therapy developer ReNeuro

Read more
8 Jul 2009 10:55

Small caps round-up: Brainjuicer, ReNeuron, Hamworthy...

Market researcher BrainJuicer, whose clients include Unilever and Nike, posted revenue growth of about 22% for the first half and said it expects to make further progress in 2009. Stem cell therapy developer ReNeuron said clinical data on its lead CTX neural stem cell line in stroke and neurodegene

Read more
30 Jun 2009 09:00

Small caps round-up: MediaZest, Reneuron, Atlantic Coal...

Display advertising and screens provider Mediazest's pre-tax profits slide in the year as administrative expenses were too high, prompting the firm to undertake further cost cutting measures. The group also said first half of 2009 has seen a drop in activity as a consequence of the economic downt

Read more
9 Jun 2009 12:21

Angel rallies on ReNeuron deal

Angel Biotechnology rallied on news that the biopharmaceutical contract manufacturer signed a GMP manufacturing deal with ReNeuron. The value of the contract was not disclosed. The signing of deal follows on from ReNeuron's recent MHRA regulatory approval to commence a clinical trial with stem cell

Read more
6789101112131415

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.